Flexion's raring to launch its knee injection Zilretta, and it's floating a $100 million-plus stock offering to make that happen.
A physician survey suggests new drugs to treat tardive dyskinesia—Neurocrine’s Ingrezza, in particular—may capture sales that beat current expectations.
Flexion's Zilretta won approval on Friday, with its official label winning praise from executives and analysts.
Goodbye to Belsomra's furry-word mascots. Now, instead of a "sleep" cat and "wake" dog, Merck has debuted a new empathy-oriented TV…
Sanofi's new diabetes and CV chief says new meds need to offer clear advantages to make it in today's tough environment.
Rep. Elijah Cummings, D-Md., is urging President Trump to press for lower prices on Biogen's multiple sclerosis drug Zinbryta.
Roche took a step toward beefing up Perjeta sales Friday with priority review for a Herceptin combo. But can the pairing really win over doctors?
Which biotech company does Vertex admire? Hint: It’s one some analysts think the CF drugmaker should bought a long time ago.
With its latest FDA nod, Bristol-Myers Squibb’s Opdivo won the right to take on Bayer's Stivaga in liver cancer.
Steve Miller, CMO of Express Scripts, is not mincing words in his assessment of Kymriah, Novartis' $475,000 CAR-T treatment for leukemia.